S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
ADIL · Adial Pharmaceuticals, Inc
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Adial Pharmaceuticals Inc (ADIL)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$3.97
+0.33
(+9.07%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$3.97
$3.97
$3.97
52-WEEK RANGE
$3.97
$1.31
$232.50
What's happening
- ADIL is up 9.07% today, trading at $3.97. — Live quote
- It's trading within 3% of its 52-week low ($1.31). (Finnhub fundamentals)
- Volume today (116) is well below its 3-month average of 60,860. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-11.25 actual vs. $-1.05 estimated (-968.2%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 6
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (10 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
ADIL
-30.55%
vs S&P 500
-43.32%
1-YEAR RETURN
ADIL
-57.93%
vs S&P 500
-72.49%
6-MONTH RETURN
ADIL
+135.80%
3-MONTH RETURN
ADIL
+39.42%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-11.25
Est. $-1.05
MISS -968.2%
2026-04-26 (Q1 2026)
$-1.48
Est. $-2.78
BEAT +46.9%
2026-01-26 (Q4 2025)
$-3.07
Est. $-2.19
MISS -40.2%
2025-10-26 (Q3 2025)
$-2.00
Est. $-3.57
BEAT +44.0%
Valuation Measures & Ratios
Enterprise Value4-$18.3M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)—
Price / Book742.36
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-1693.21%
Return on Assets (ROA9)-495.62%
Avg Volume (3M)60,860
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $12.2M | $2.4M | $198.9M | $3.2M | $4.1M |
| P/E | -0.21 | -0.30 | -24.34 | -0.36 | -0.31 |
| Price/Book | -0.32 | 0.65 | 44.16 | 0.57 | 1.92 |
| ROE | 150.52% | -215.33% | -181.40% | -158.09% | -628.21% |
| ROA | -198.58% | -153.11% | -144.39% | -129.92% | -386.99% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short183,323
Change from Prior Settlement-12.70%
% of Float—
Days to Cover (Short Ratio)4.28
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-16; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -57.9%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ADIL
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$52.0M | -$2.0M | -$1.8M | -$1.9M | -$2.3M | -$2.2M | -$2.3M | -$1.8M |
| Net income | -$52.0M | -$2.0M | -$1.8M | -$2.0M | -$2.2M | -$2.2M | -$2.5M | -$6.5M |
| EPS (diluted) | $-11.25 | $-1.48 | $-0.08 | $-4.61 | $-8.52 | $-0.38 | $-0.59 | $-2.19 |
| EPS (basic) | $-11.25 | $-1.48 | $-0.08 | $-4.61 | $-8.52 | $-0.38 | $-0.59 | $-2.19 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $29.1M | $5.2M | $6.7M | $5.7M | $6.8M | $3.5M | $5.0M | $6.7M |
| Total liabilities | $28.9M | $1.5M | $1.4M | $1.2M | $1.2M | $1.3M | $975.9K | $829.0K |
| Stockholders' equity | -$38.4M | $3.7M | $5.3M | $4.5M | $5.6M | $2.1M | $4.1M | $5.9M |
| Total current assets | $28.8M | $4.8M | $6.2M | $5.0M | $6.1M | $2.6M | $4.1M | $5.6M |
| Total current liabilities | $5.1M | $1.5M | $1.4M | $1.2M | $1.2M | $1.3M | $975.9K | $829.0K |
| Cash & equivalents | — | — | $5.9M | $4.6M | $5.9M | $2.4M | $3.8M | $5.2M |
| Property, plant & equipment | — | — | — | — | — | — | — | — |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible assets | $3.0K | $2.6K | $3.0K | $2.9K | $3.1K | $3.2K | $3.3K | $3.5K |
| Other non-current assets | — | — | — | — | — | — | — | — |
| Accounts payable | $2.6M | $573.6K | $655.0K | $556.3K | $671.1K | $532.4K | $250.1K | $318.1K |
| Accrued liabilities | $2.5M | $936.5K | $742.0K | $598.5K | $539.9K | $758.7K | $677.5K | $500.9K |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $3.0K | $1.5K | $1.0K | $23.8K | $21.5K | $6.7K | $259 | $6.4K |
| Retained earnings | -$144.0M | -$92.0M | -$90.0M | -$88.0M | -$86.2M | -$84.2M | -$82.0M | -$79.9M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.4M | -$1.6M | -$1.3M | -$1.8M | -$1.7M | -$1.6M | -$1.5M | -$1.7M |
| Investing cash flow | $5.3M | — | $0 | $0 | $0 | $150.0K | — | — |
| Financing cash flow | $25.2M | $315.3K | $2.6M | $524.8K | $5.3M | $50.6K | $0 | $3.6M |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Share-based compensation | $137.1K | $147.9K | $168.0K | $147.2K | $124.3K | $236.7K | $180.2K | $188.3K |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts payable | $1.7M | -$81.6K | — | -$113.8K | $137.7K | $282.3K | — | $1.4K |
| Share repurchases | — | — | — | — | — | — | — | — |
| Other financing activities | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$7.8M | -$8.3M | -$6.9M | -$10.9M | -$19.3M |
| Net income | -$8.0M | -$13.2M | -$5.1M | -$12.7M | -$19.4M |
| EPS (diluted) | $-11.93 | $-68.01 | $-3.60 | $-12.71 | $-1.04 |
| EPS (basic) | $-11.93 | $-68.01 | $-3.60 | $-12.71 | $-1.04 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $6.7M | $5.0M | $4.7M | $5.7M | $7.5M |
| Total liabilities | $1.4M | $975.9K | $653.1K | $2.5M | $4.0M |
| Stockholders' equity | $5.3M | $4.1M | $4.1M | $3.3M | $3.5M |
| Total current assets | $6.2M | $4.1M | $3.2M | $4.8M | $6.5M |
| Total current liabilities | $1.4M | $975.9K | $653.1K | $1.8M | $2.7M |
| Cash & equivalents | $5.9M | $3.8M | $2.8M | $4.0M | $6.1M |
| Property, plant & equipment | — | — | — | $50.4K | $58.1K |
| Goodwill | — | — | — | $249.0K | $249.0K |
| Intangible assets | $2.8K | $3.3K | $3.9K | — | — |
| Other non-current assets | — | — | — | — | — |
| Accounts payable | $655.2K | $250.1K | $103.3K | $276.4K | $286.2K |
| Accrued liabilities | $741.7K | $677.5K | $477.7K | $963.3K | $2.4M |
| Other current liabilities | — | — | — | $10.4K | $9.7K |
| Common stock & paid-in capital | $1.1K | $259 | $1.7K | $1.1K | $20.9K |
| Retained earnings | -$90.0M | -$82.0M | -$68.8M | -$63.7M | -$50.9M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$6.5M | -$6.9M | -$6.8M | -$11.2M | -$11.9M |
| Investing cash flow | $150.0K | — | $1.5M | — | -$34.0K |
| Financing cash flow | $8.5M | $7.8M | $4.1M | $9.1M | $13.6M |
| Free cash flow | — | — | — | — | -$12.0M |
| Capital expenditures | — | — | — | — | $64.6K |
| Share-based compensation | $676.2K | $796.8K | $1.7M | $3.4M | $4.2M |
| Deferred income taxes | — | — | — | -$502 | -$94.1K |
| Change in accounts payable | — | — | -$183.5K | $15.8K | -$353.8K |
| Share repurchases | — | — | $1.7K | — | — |
| Other financing activities | — | — | $749.9K | $9.1M | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ADIL as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-04-07 to 2026-07-16
Recent transactions
- Insiders have net bought 39,986 shares over the last 182 days, across 5 purchases and 0 sales.
- Most recent: Coastlands Capital LP (10% owner) — Open market purchase of 1,233 shares on 2026-07-16.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)39,986 sh(5 txns)
Sales (open market)0 sh(0 txns)
Net Shares+39,986
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Coastlands Capital LP | 10% owner | Open market purchase | 2026-07-16 | 1,233 |
| Davidson Matt | Chief Development Officer | Grant / award | 2026-06-12 | 232,417 |
| Goodman Tony | Chief Operating Officer | Grant / award | 2026-04-07 | 26,510 |
| Schuyler Kevin | Director | Grant / award | 2026-04-07 | 9,185 |
| Shah Vinay | Chief Financial Officer | Grant / award | 2026-04-07 | 17,325 |
| Gilliland Robertson H. | Director | Grant / award | 2026-04-07 | 9,185 |
| Claiborne Cary J | Chief Executive Officer | Grant / award | 2026-04-07 | 37,985 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-16 | Coastlands Capital LP | 10% owner | Open market purchase | 1,233 | $2.75 |
| 2026-07-14 | Coastlands Capital LP | 10% owner | Open market purchase | 2,000 | $2.65 |
| 2026-07-10 | Coastlands Capital LP | 10% owner | Open market purchase | 1,700 | $2.70 |
| 2026-07-09 | Coastlands Capital LP | 10% owner | Open market purchase | 10,053 | $2.79 |
| 2026-06-29 | Coastlands Capital LP | 10% owner | Open market purchase | 25,000 | $2.60 |
| 2026-06-12 | Davidson Matt | Chief Development Officer | Grant / award | 232,417 | $0.00 |
| 2026-06-11 | Davidson Matt | Chief Development Officer | Grant / award | 61,647 | — |
| 2026-06-11 | Davidson Matt | Chief Development Officer | Grant / award | 3,427 | — |
| 2026-06-11 | Davidson Matt | Chief Development Officer | Grant / award | 1,822 | — |
| 2026-06-11 | Davidson Matt | Chief Development Officer | Grant / award | 101 | — |
| 2026-04-07 | Goodman Tony | Chief Operating Officer | Grant / award | 26,510 | $0.00 |
| 2026-04-07 | Schuyler Kevin | Director | Grant / award | 9,185 | $0.00 |
| 2026-04-07 | Shah Vinay | Chief Financial Officer | Grant / award | 17,325 | $0.00 |
| 2026-04-07 | Gilliland Robertson H. | Director | Grant / award | 9,185 | $0.00 |
| 2026-04-07 | Claiborne Cary J | Chief Executive Officer | Grant / award | 37,985 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:28 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-16 | 8-K | 2026-10-15 | View on SEC.gov → |
| 2026-10-02 | 8-K | 2026-10-01 | View on SEC.gov → |
| 2026-09-21 | 4 | 2026-09-17 | View on SEC.gov → |
| 2026-09-18 | 8-K | 2026-09-17 | View on SEC.gov → |
| 2026-09-16 | 8-K | 2026-09-16 | View on SEC.gov → |
| 2026-08-25 | 8-K | 2026-08-19 | View on SEC.gov → |
| 2026-08-21 | 8-K | 2026-08-18 | View on SEC.gov → |
| 2026-08-17 | 8-K | 2026-08-17 | View on SEC.gov → |
| 2026-08-14 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-10 | View on SEC.gov → |
| 2026-07-16 | 4 | 2026-07-14 | View on SEC.gov → |
| 2026-07-13 | 4 | 2026-07-09 | View on SEC.gov → |
Recent news
Headlines about ADIL (Adial Pharmaceuticals, Inc). Links open the publisher — we don’t host full articles.
-
Freeths advises The Adil Group on acquisition of 22 KFC restaurants | Drinks, Hospitality & Leisure | Freeths
Freeths · 2026-10-19 -
Adil Jal Darukhanawala’s Kinetic’s Electric Energy decodes five decades of Indian automotive innovation
The Indian Express · 2026-10-18 -
Adial Pharmaceuticals Stock Price Forecast. Should You Buy ADIL?
StockInvest.us · 2026-10-16 -
Adial Pharmaceuticals appoints David Rubenstein as chief scientist
TipRanks · 2026-10-16 -
Adial Pharmaceuticals appoints David Rubenstein as chief scientist By Investing.com
Investing.com Canada · 2026-10-16 -
Adial Pharmaceuticals Appoints AhR Drug Development Veteran David Rubenstein as Chief Scientist to Advance AT177 for Ulcerative Colitis
Quiver Quantitative · 2026-10-16 -
Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis
Yahoo Finance · 2026-10-16 -
ADIL DEFA14A & SEC Filings
Yahoo Finance · 2026-10-16
No headlines in this category right now — try “All”.